Preventive health, AI-driven science, and changing consumer behavior are changing how the world approaches aging and extending health.
Aging has always been seen as something to manage around the edges, not as something to design. This is changing quickly.
According to new information from SNS InsiderThe global longevity market is expected to grow from USD 27.61 billion in 2025 to USD 67.03 billion in 2035, mainly driven by increasing health concerns worldwide (1). In simpler terms, more people are not only living longer, but living with conditions they wish they could prevent, delay, or better understand.
And this shift is turning longevity into an economic system built around one question: how do we stay healthier, not just older?
The most important change in this market is not a single breakthrough drug or technology. This is a behavior reversal. Across regions, health care is slowly shifting from reactive to preventive treatment. This means catching risk earlier, tracking biological changes over time, and intervening before the disease takes root.
Longevity tools are becoming increasingly popular as a practical extension of daily health care. Traditional medicine often kicks in when the body’s engine fails. Rather, longevity is about monitoring wear and tear before it breaks down.
This is reflected in the market structure. Preventive health and wellness currently holds the largest share of the program, accounting for just over 30% of the market. This is a sign that consumers are increasingly willing to invest in not just getting well, but staying well.
The rise of the “self-managed” healthcare era
One of the more interesting insights from the report is the central role people have come to play. Consumers account for over 35% of the market, the largest end-user segment. This means longevity is no longer limited to clinics, research labs or biotech pipelines. It is now something that people actively incorporate into their lives.
Nutrients and dietary supplements dominate the market, accounting for more than 28% in 2025. Although this may sound familiar, the context is different now. These products are no longer seen as side effects, but as entry points into long-term health strategies.
We are also seeing a strong shift to direct-to-consumer ecosystems. People no longer expect health care systems to “offer” longevity. They buy it, subscribe to it, and follow it themselves.
In a way, longevity is becoming a personal infrastructure. Calm, continuous and increasingly normalized.
Biology becomes information
Behind the consumer-facing layer, more technical change is taking place, but it needs to be translated. Fields like genomics and epigenetics are helping scientists understand not only which genes we have, but also how those genes are turned on or off over time. If DNA is the script, epigenetics is the director of what scenes are actually played. This is why genomics and epigenetics now dominate the technology segment, accounting for more than 24% of the market share.
At the same time, newer tools such as biomarker and clock aging technologies are emerging rapidly. These systems attempt to calculate “biological age” and essentially ask if your body is aging faster or slower than the calendar.
It’s a bit like comparing a car’s mileage to its looks and performance. Two people may both be 50 years old, but biologically, they may be in very different states of health. This type of measurement changes the definition of longevity from something abstract to something trackable.
An experiential advantage: the goal of aging itself
Perhaps the most promising corner of the market is in therapies that aim not only to cure disease, but also to intervene in the aging process.
One of the fastest growing areas is senolytics and xenotherapeutics, which are designed to target “senescent cells,” or damaged cells that stop functioning properly but do not die as they should. Over time, these cells accumulate and are believed to contribute to inflammation and age-related decline.
You can think of them as “stopped cars” blocking the highway for mobile. Cleaning them up is one way researchers hope to improve the overall flow of the system.
This segment is projected to grow at the fastest rate over the next decade, fueled by both scientific momentum and investor interest in what aging interventions look like beyond symptom management.
However, this remains a frontier space – promising, but early. Like much of longevity science, it sits somewhere between possibility and evidence.
Geographically, the story is the same. North America is currently leading the longevity market with a share of around 40% by 2025. The region’s strong biotech ecosystem, high consumer awareness and established healthcare infrastructure continue to drive adoption.
However, the fastest pace is happening elsewhere. Asia Pacific is expected to be the fastest growing region by 2035, driven by aging populations and rising health awareness in China, Japan, South Korea and India.
Infrastructure behind the boom
The business growth envisioned by SNS Insider is reflected through a robust and rapidly maturing biotech pipeline as seen through its lens. DLT platform. According to the latest analysis of the DLT landscape, there are now 657 prominent companies managing 2,785 tracked therapeutic assets, indicating that the biology of aging is no longer a prize interest, but a deep pillar of the industry.
This market is expanding into a complex multi-mechanism platform. DLT’s granular tracking shows that cellular aging alone is the target of 1,185 assets across 396 companies, while topics such as chronic inflammation and altered intercellular communication are emerging even more. While the US remains the main anchor with 380 companies, DLT finds significant international depth emerging from the UK, South Korea, France and Switzerland.
Ultimately, this suggests that as consumer demand for preventive health intensifies, the basic biotechnological infrastructure— carefully mapped by DLT – is already positioned to support a much larger long-term economy. For those willing to navigate this complex web of assets and players, data suggests that the “frontier” has already become an established map.
Beyond the $67 billion figure
It’s easy to look at the $67.03 billion outlook by 2035 and dismiss it as another phase of the market, but the bigger story is direction.
What we are witnessing is a gradual change in the definition of aging itself: from something passive and inevitable to something measurable, manageable and influenced by science and technology. This is already being seen in human behavior, from tracking sleep and metabolic health to experimenting with personalized nutrition and preventative treatments. This is also clear about how companies are built.
However, the most important subtlety remains unchanged. Longevity is about extending the life span in which people feel capable, functional, and well. If the last decade has been about living longer, then the next decade may be about learning how to design the aging experience.
The longevity market is about something bigger than just its value. It becomes a reflection of how we want to live, not just how much.
(1) SNS-Insider.html
